196 related articles for article (PubMed ID: 8797594)
1. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
5. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
6. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
7. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
8. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
9. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
10. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
11. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
12. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.
Ferlin-Bezombes M; Jourdan M; Liautard J; Brochier J; Rossi JF; Klein B
J Immunol; 1998 Sep; 161(6):2692-9. PubMed ID: 9743325
[TBL] [Abstract][Full Text] [Related]
13. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
14. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
Tassone P; Galea E; Forciniti S; Tagliaferri P; Venuta S
Int J Oncol; 2002 Oct; 21(4):867-73. PubMed ID: 12239628
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.
Hooper WC; Phillips DJ; Evatt BL
Thromb Haemost; 1997 May; 77(5):1014-9. PubMed ID: 9184420
[TBL] [Abstract][Full Text] [Related]
17. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
de Hon FD; Ehlers M; Rose-John S; Ebeling SB; Bos HK; Aarden LA; Brakenhoff JP
J Exp Med; 1994 Dec; 180(6):2395-400. PubMed ID: 7964514
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
[TBL] [Abstract][Full Text] [Related]
19. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
20. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion.
Fischer M; Goldschmitt J; Peschel C; Brakenhoff JP; Kallen KJ; Wollmer A; Grötzinger J; Rose-John S
Nat Biotechnol; 1997 Feb; 15(2):142-5. PubMed ID: 9035138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]